

INDEX

- Accessibility of healthcare, 4
Accident and Emergency hospital departments (A&E hospital departments), 50
Accord National Interprofessionnel (ANI), 179
Activity-based funding, 88–89
Activity-based reimbursement of hospitals, 108–111
Acute myocardial infarction (AMI), 49
Adult Social Care (ASC), 44, 51, 53
 future challenges, 53–55
Age profiles, 36–37
Agence Nationale d'Accreditation et d'Evaluation en Santé (ANAES), 171–172
Agences Régionales d'Hospitalisation (ARH), 171–172
Aide Complémentaire Santé (ACS), 179
Alcohol, 158–159
Ambulatory care, sustainability in, 172–174
Annual co-payment caps, 147
Antibiotics, 177
Antimicrobial resistance (AMR), 177
Association of Directors of Adult Social Services (ADASS), 52
Assurance Maladie (SHI), 168, 184
Austria, 153–155
Austrian Health Targets, 155
Austrian healthcare system, 154–155
 challenges, 158–164
 healthcare interventions and efficacy, 155–158
Bed blockers, 94
Best practice tariffs (BPT), 50
Bismarck model, 120–121
Bismarckian model, 141, 190
Budget capping, 201–203
Canadian Occupational Performance Measure (COPM), 85
Cancer plan, 15
Cardiovascular diseases (CVDs), 25, 29
 by Eastern countries, 30
 frequencies by cohorts, 32, 35
Care Act (2014), 51
Care Quality Commission (CQC), 44–45
Catalan autonomous region (CCAA), 196
Catch-up programmes, 95–96
Central Statistics Office (CSO), 68–69
Centralisation reform, 110
Challenges, 83
Clinical Commissioning Groups (CCGs), 44–45
Coefficient of variation (CV), 196–197
Cohort analysis, 26
Collective contracts, 178–179
Colorectal cancer, 8
Commercialisation, 123–124
Commission d'évaluation économique et de santé publique (CEESP), 172, 177
Commissioning for Quality and Innovation framework (CQUIN framework), 50
Community public health objectives, 3
Complementary health insurance (CHI), 168, 170
 ‘employers’ provision of, 178–179
 sustainability in, 178–181
Conditional order-m FDH approach, 148–149

- Coordination between sub-sectors of health care, 94–95
- Coordination Reform (2012), 94–95
- Copayments, 82
- Corruption, 133–134
- Cost sharing
 - measures, 146–147
 - policy, 12–13
- Country-specific recommendations (CSR), 6
- Couverture Maladie Universelle Complémentaire (CMU-C), 179–180
- COVID-19, 61–62, 75, 232
 - challenges from, 16–17
 - and future pandemics, 162–164
 - pandemic, 3, 23–24
- Cultural changes, 133–134
- CZ-DRG project, 149
- Czech health care system, 139–140
 - features, 140–144
 - payment mechanisms, 143–144
 - provision of health care, 143
 - reforms and challenges toward sustainability, 144–150
 - SHI system, 141–142
- Czech Republic, 139–140
- Czech statutory health insurance scheme, 141

- Danish GPs, 105
- Danish Health Care system, 104–106
- Data envelope analysis (DEA), 88
- Decentralisation of health-care spending, 195–198
- Denmark, 104
 - evidence and possibilities of future research, 113–115
 - health care expenditure in, 107
 - reforms to improving quality of care, 110–113
 - reforms to increasing activity and reducing waiting time, 107–110

- Dental consultations, 210
- Department of Health (DH), 45–46
- Department of Health and Social Care, 44–45
- Deprivation, 47
- Diagnosis-related groups (DRGs), 76–77, 83, 88–89, 108–109, 144, 174
 - DRG-based funding, 174
 - DRG-Restart project, 149
 - prices, 109–110
 - system, 149
- Diagnostic services, 210
- Disease Management Programs (DMP), 112–113
- Disease prevalence, 23–24, 28
 - average marginal effects by region, 36–37, 40, 42
 - cancer frequencies by cohorts, 31, 34
 - data, 24–26
 - descriptive statistics, 27
 - diabetes frequencies by cohorts, 32, 35
 - frequencies of observations, 25–26
 - lung disease frequencies by cohorts, 31, 34
 - by region and cohort, 26–36
 - test for differences, 33
- Drug(s), 158–159
 - pricing, 177–178

- EC Initiative on Breast Cancer, 8
- Educational policy, 132
- Efficiency, 148–150
- ‘Employers’ provision of complementary health insurance, 178–179
- Employment control framework (ECF), 76–77
- England, 44
- English health and social care system, 44–45
- Epidemics, 234–235

- Ethnographic study, 46
- EuroHOPE project, 89
- Europe, 3
- European Economic Area (EEA), 92
- European Fund for Strategic Investments, 5
- ‘European Guide for Quality National Cancer Control Programmes’, 8
- European Partnership for Action Against Cancer, 7
- European Regional Development Fund (ERDF), 5
- European regions, 26, 29, 33, 36
- European Semester, 6, 11, 13
- European Social Charter, 12
- European Social Fund (ESF), 5
- European Travel Information and Authorisation System (ETIAS), 232
- European Union (EU), 2, 199, 235
- actions, 2
 - actions through internal market, 9–11
 - collaboration between member states, 13–14
 - European Semester, 11–13
 - evidence on selected EU actions, 6–15
 - fighting cancer, 7, 9
 - future EU actions on health, 15–17
 - health information for
 - evidence-based policy, 14–15
 - health strategy, 3–4
 - health systems, 2
 - legal background, 3
 - policy instruments, 4–6
 - potential for externalities, 13–15
 - role and actions of, 3–6
- Evidence-based policy, 14–15
- Exemptions, 147
- Family health units, 213
- Faster return to work scheme (FRW scheme), 84
- Fee-for-service (FFS), 105, 144
- payment mechanisms, 71
- Financial
- resources for health sector, 126–131
 - sustainability, 214–215
- Financing
- health care in French health care system, 168–170
 - issues, 54
- Fiscal space, 219
- Five Year Forward View (FYFV), 51
- Fixed-effect models, 88–89
- Framework programmes (FPs), 4–5
- France, 168
- French Health Authority, 172
- French health care system, 168
- financing health care in, 168–170
 - key reforms in, 170–172
 - sustainability in, 172, 181, 183–184
- French Medicines Agency, 175–176
- Full-time equivalent (FTE), 47
- Funding, 47–48
- Gate-keeping system, 173–174
- General Health Insurance Fund (GHIF), 141
- General Medical Services (GMS), 45–46
- General Practice Forward View (GPFV), 47
- General practitioners (GPs), 44–45, 62–63, 82, 86, 104–105, 156
- Generic drugs, 175–176
- Government deficit, 217–220
- Gross domestic product (GDP), 44, 62, 202–203, 234
- Gross national income (GNI), 64
- Harmonisation of cancer screening, 7–9

- Haute Autorité de Santé* (HAS), 171, 182
- Health
- economics, 76
 - information for evidence-based policy, 14–15
 - insurance, 168
 - policy, 3, 118, 235
 - screening and prevention, 155–156
 - shocks, 235
 - spending sustainability, 217, 220–221, 223
 - strategy, 3–4
 - systems, 2
 - workforce, 10–11
- Health and Social Care Act (2012), 44–45
- Health care expenditure (HCE), 62, 146–147, 168, 170
- Health Programme (HP), 4–5
- Health Service Executive (HSE), 76–77
- Health technology assessment (HTA), 4, 10, 73, 171–172, 200
- Health-care, 235
- access to healthcare in rural areas, 159–162
 - coordination between sub-sectors of, 94–95
 - financing, 44–45
 - services, 63
 - system in Poland, 118
 - utilisation of refugees, 162
- Healthcare resource groups (HRGs). *See also* Diagnosis-related groups (DRGs), 48
- Heart attack, 49
- Horizon 2020 (H2020), 9
- Hospital, 170
- cost containment, 148–150
 - at home, 175
- Hospitalisation à domicile* (HAD), 175
- House of Lords, 54–55
- HPV vaccination, 95–96
- Human resources, 131–133
- Immunisation, 157
- Index price, 92
- Informal care, 52
- Information and Quality Authority (HIQA), 76–77
- Integrated/coordinated health care, 126
- Interministerial Commission on Pharmaceutical Prices (ICPP), 201
- International Classification of Primary Care system (ICPC system), 112–113
- International co-ordination, 235
- International Non-proprietary Name (INN), 175–176
- Investments in health workforce, 147–148
- Ireland, 61–62
- Ireland's health care system, 61–62
- challenges to sustainability, 68–72
 - features of Irish health care system, 62–64
 - policy, 72–74
 - recent trends in public health care expenditures, 64–68
 - sustainability, 62
- Italy
- avoiding mixed signals, 233
 - doing policy announcements right, 233–234
 - local chains of transmission, 232–233
 - need for comprehensive policy packages, 234
 - sub-optimality of flight bans, 232–234
- Linear probability model, 36–37
- Local health units, 213
- Loi de Financement de la Sécurité sociale* (LFSS), 171

- Long-term care (LTC), 82, 90–91
 Long-term illnesses scheme, 178
- Maastricht Treaty (1992), 3
 Mammography screening, 96
 Maternal and child health, 156–157
 Maternity leave, 157
 Maximum pharmacy retail price, 93
 Maximum price for drug, 93
 Means-tested medical care system, 62–63
 Medical devices, 9–10
 Ministry of Health (MoH), 201
 Mother-Child-Pass programme, 156
 Multispecialty Community Provider, 55
- National Audit Office (NAO), 54
 National Health and Hospital Plan (2016–19), 94
 National Health Fund (NHF), 119–120
 voivodships branches, 122
 National Health Insurance Systems (NHIS), 190
 National Health Service (NHS) (*See also* Portuguese NHS), 44, 209
 Constitution, 50
 future challenges, 53–55
 Improvement, 44–45
 primary care in, 45–48
 providers, 48
 National Insurance Scheme (NIS), 82
 Networks of contracted providers, 180–181
 ‘New Health Strategy’, 3–4
 New models of delivery, 54–55
 Norway, 82, 84, 95
 Norwegian health care system, 82
 coordination between sub-sectors of health care, 94–95
 LTC, 90–91
 pharmaceuticals, 92–93
 primary care, 85–88
 screening for cancer, 95–96
 specialist care, 88–89
 system of prioritisation of health services, 84–85
- Norwegian Medicines Agency (NOMA), 84–85
 Norwegian Patient Register, 88–89
- Objectif national de dépenses d’assurance maladie* (ONDAM), 171
 Opposable Medical References, 173
 Organisation for Economic Co-operation and Development (OECD), 190
 Out-of-pocket (OOP), 168, 172
- Parental leave, 157
 Patient Choice, 45
 Patient mobility, 10–11
 Payment by Results (PbR), 45, 48–49
 Payment mechanisms, 143–144
 Personal care, 52–53
 Pharmaceutical(s), 9–10, 92–93
 expenditure, 70–71
 roadmap, 16
 spending, 200
 sustainability in, 175–178
- Physiotherapists, 133
Plan antibiotique, 177
Plan Juppé, 171–172
Points d’accueil pour soins immédiats (PASI), 184
- Policy instruments, 4–6
 Polish health care system, 118
 ageing of polish population and health care system, 119–122
 cultural changes and corruption, 133–134
 expenses for health care in selected EU countries, 129
 financial resources for health sector, 126–131

- human resources, 131–133
- integrated care programs and pilots, 127–128
- misguided organisation of health sector and health care entities, 122–126
- Population ageing, 158
- Portugal health spending, 210–212
- Portuguese health system, 210
- Portuguese NHS, 209–214
 - challenges for NHS and sustainability problem, 214–216
 - forecasting expenditures in, 216–223
 - health spending in Portugal, 210–212
 - health spending sustainability and government deficit, 217–220
 - health spending sustainability and public debt, 221–223
 - new policies in, 213–214
 - sustainability, 224–227
- Primary and Acute Care Systems, 55
- Primary care, 45, 48, 82, 85, 88, 104–105, 171
 - units, 213
- Primary Care Reform (2015), 94
- Primary Care Trusts (PCTs), 45
- Primary healthcare, 159
- Primary Healthcare Act, 126
- Priorities, 82
- Private health insurance (PHI), 63, 106
- Private spending in Spain, 192–194
- Proportionality principle, 2
- Public debt, 221–223
- Public Health and Social Policy, 3
- Public health care expenditures, recent trends in, 64–68
- Public health/preventative care, 55
- Public provision and production, 190–192
- Public spending in Spain, 192–194
- Quality and Outcomes Framework (QOF), 45–46, 112–113
- Recovery plan for Europe, 16
- Reference pricing, 92
- Références Médicales Opposables* (RMO), 173
- Reforms, 84, 168
- Refugees, healthcare utilisation of, 162
- Regional financing of health care, 198–199
- Regional Health Authorities (RHA), 82–83
- Rehabilitation, 210
- Reimbursement based on added therapeutic value, 176
- Research and innovation, 5–6
- Resilient health system, 4
- Responsible contracts, 179
- Risky behaviour, 154
- Screening for cancer, 95–96
- Secondary care. *See also* Primary care, 48, 51, 105–106
- Self-support principle, 123–124
- Semashko model, 140–141
- Service médical rendu* (SMR), 176
- Seventh Framework Programme (FP7), 9
- Severe mental illness (SMI), 46
- Sláintecare, 73–74
- Small and medium enterprises (SMEs), 234
- Social health insurance system (SHI system), 140–142, 144, 146, 168
- Social Security (1945), 182
- Socio-economic status (SES), 23–24
- Spanish Agency of Medicinal Products and Medical Devices (AEMPS), 201

- Spanish Fiscal Authority, 201
- Spanish health-care system, 190, 195, 199
- in context of Western health care, 190
 - decentralisation of health-care spending, 195–198
 - pharmaceutical expenditure, 199–203
 - public and private spending in Spain, 192–194
 - public provision and production, 190–192
 - regional financing of health care, 198–199
 - Spanish decentralisation, 196–198
 - traits, 194–195
- Spanish pharmaceutical sector, key trends in, 199–201
- Specialist care, 82–83, 88–89
- SPZOs, 123–124
- Stability and Growth Pact, 3
- Stochastic frontier analysis, 148–149
- Structural funds, 5
- Structural modelling, 92
- Subsidiarity principle, 2
- Survey of Health, Ageing and Retirement (SHARE), 24, 26, 29, 32
- Sustainability, 44, 83, 113, 118, 153–154
- challenges to, 68–72
 - in complementary health insurance, 178–181
 - demand side factors, 68–69
 - in French health care system, 172, 181, 183–184
 - of health system, 2, 4
 - at hospital, 174–175
 - of Ireland's health care system, 62
 - in pharmaceuticals, 175–178
 - supply side factors, 69–72
- Sustainability and transformation plans (STPs), 51
- Tariff-based activity, 174–175
- Tertiary care, 48–51
- Tobacco, 158–159
- Total cost (TC), 104–105
- Two-tier system, 63
- UK Parliament Select Committee, 53
- Universal complementary health insurance, 179–180
- Universal Health Coverage (UHC), 118
- Urgent and Emergency Care Networks, 55
- User fees, 146–147
- Vaccinations, 157–158
- Velvet Revolution, 139–141
- Waiting time guarantee, 109
- 'What works', 2
- Workforce/recruitment, 54
- World Health Organisation (WHO), 168